Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 29, 2026
DataAggregated Company Financials
Companies21
  • 7D1.1%
  • 3M12.6%
  • 1Y-33.0%
  • YTD11.4%

Over the last 7 days, the Healthcare industry has risen 1.1%, driven by gains from Novo Nordisk of 2.0%. In the past year, the industry is down 33%. As for the next few years, earnings are expected to grow by 4.5% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 29 Jan 2026DKK 2.2tDKK 453.2bDKK 136.7b17.7x15.9x4.8x
Sat, 27 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Mon, 24 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b17.1x13.5x4.1x
Wed, 22 Oct 2025DKK 2.1tDKK 447.6bDKK 141.8b19.2x14.9x4.7x
Fri, 19 Sep 2025DKK 2.2tDKK 447.2bDKK 141.6b19.1x15.8x5x
Sun, 17 Aug 2025DKK 1.9tDKK 444.4bDKK 140.2b28.1x13.6x4.3x
Tue, 15 Jul 2025DKK 2.4tDKK 423.2bDKK 124.5b29.9x19.4x5.7x
Thu, 12 Jun 2025DKK 2.8tDKK 423.6bDKK 124.6b31.3x22.3x6.6x
Sat, 10 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Mon, 07 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b22.8x19.4x5.8x
Wed, 05 Mar 2025DKK 3.3tDKK 410.0bDKK 121.4b26.9x26.8x7.9x
Fri, 31 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b28.6x29.2x8.4x
Sun, 29 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Tue, 26 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31.2x34.7x10x
Thu, 24 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b34.2x38.4x11.1x
Sat, 21 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Mon, 19 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.2x43.9x12.7x
Wed, 17 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.2x46.1x13.8x
Fri, 14 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b36.4x46.6x13.9x
Sun, 12 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Tue, 09 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.9x13.1x
Thu, 07 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38.2x44.3x12.9x
Sat, 03 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Mon, 01 Jan 2024DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Wed, 29 Nov 2023DKK 3.6tDKK 320.4bDKK 90.0b33x39.7x11.2x
Fri, 27 Oct 2023DKK 3.5tDKK 305.7bDKK 82.3b26.7x42.5x11.4x
Sun, 24 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Tue, 22 Aug 2023DKK 3.3tDKK 303.6bDKK 81.3b36.3x40.8x10.9x
Thu, 20 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.7x10.2x
Sat, 17 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Mon, 15 May 2023DKK 3.2tDKK 284.8bDKK 74.9b41.2x43.1x11.3x
Wed, 12 Apr 2023DKK 3.0tDKK 272.6bDKK 68.5b42.9x43.7x11x
Fri, 10 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.5x40.7x9.6x
Sun, 05 Feb 2023DKK 2.7tDKK 285.9bDKK 69.0b38.1x38.9x9.4x
Price to Earnings Ratio

38.9x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 69.0bTotal Revenue: DKK 285.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 15.9x which is lower than its 3-year average PE of 33.4x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 17% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.31%
Healthcare1.09%
Healthcare Services11.43%
Pharma1.83%
Biotech-1.51%
Healthtech-1.68%
Medical Equipment-2.47%
Life Sciences-3.70%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 293x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SMSMED Scandinavian Medical SolutionsDKK 4.077.1%
+DKK 7.5m		-24.1%PE4352.7x
VIRO ViroGatesDKK 11.554.1%
+DKK 4.2m		-9.8%PS13.2x
PEG Pharma Equity GroupDKK 0.111.0%
+DKK 1.2m		-32.5%PB3.3x
MONSO MonsensoDKK 0.157.0%
+DKK 746.0k		-52.8%PS1x

Latest News

ALK B
DKK 210.40
ALK-Abelló
7D
-4.7%
1Y
36.4%
SMSMED
DKK 4.07
Scandinavian Medical Solutions
7D
7.1%
1Y
-24.1%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
HLUN B
DKK 41.68
H. Lundbeck
7D
-6.0%
1Y
-3.6%

HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook

Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.
ZEAL
DKK 411.90
Zealand Pharma
7D
-5.0%
1Y
-43.7%

ZEAL: Metabolic Collaboration Will Support Future Upside As Margins Strengthen

Analysts see Zealand Pharma’s fair value estimate broadly unchanged at around €745.93 per share. The updated target reflects slightly firmer profit margin assumptions at 26.94%, a modestly smaller 36.49% revenue decline, and a lower forward P/E of 94.77x, partly offset by a marginally higher 5.17% discount rate.
COLO B
DKK 541.40
Coloplast
7D
-2.1%
1Y
-35.2%

Coloplast A/S' (CPH:COLO B) P/E Is On The Mark

Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
DEMANT
DKK 219.80
Demant
7D
-6.1%
1Y
-25.1%

DEMANT: Stable Guidance And Sector Perform Rating Will Support Future Earnings Resilience

Analysts have reduced their price target on Demant by roughly DKK 2 to about DKK 266, reflecting only modest adjustments to growth, margin and P/E assumptions and citing limited scope for the company to increase its organic revenue share over the medium term. Analyst Commentary Recent research paints a fairly balanced picture for Demant, with the current DKK 250 price target and Sector Perform rating pointing to a view that the shares are reasonably valued on existing growth and margin assumptions.
NOVO B
DKK 370.40
Novo Nordisk
7D
-6.6%
1Y
-38.6%

NOVO B: Wegovy Pill Launch And Execution Discipline Will Support Future Upside

Analysts have reduced their fair value estimate for Novo Nordisk to €540 from €612. They cite more moderate assumptions for revenue growth and profit margins, along with a higher discount rate and a slightly higher expected future P/E multiple.
GMAB
DKK 2,067.00
Genmab
7D
-2.4%
1Y
46.6%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
VIRO
DKK 11.55
ViroGates
7D
4.1%
1Y
-9.8%
PEG
DKK 0.11
Pharma Equity Group
7D
1.0%
1Y
-32.5%
CHEMM
DKK 610.50
ChemoMetec
7D
-13.2%
1Y
9.4%
MONSO
DKK 0.15
Monsenso
7D
7.0%
1Y
-52.8%